Borviz 2.5 mg

Name: Borviz 2.5 mg
Brand: Maheshwari Medical Agency
Price: 2600 INR
Availability: InStock

Price 2600 INR/ Vial

Get a Price/Quote

MOQ : 2 Vials

Borviz 2.5 mg Specification

Dosage Form
Powder for Solution for Injection

Indication
Treatment of Multiple Myeloma, Mantle Cell Lymphoma

Life Span
24 months from manufacturing

Salt Composition
Bortezomib 2.5 mg

Packaging Type
Vial

Origin of Medicine
India

Brand Name
Borviz

Pacakaging (Quantity Per Box)
1 Vial per box

Drug Type
Antineoplastic agent

Ingredients
Bortezomib

Physical Form
Injection

Function
Anti-cancer/Proteasome inhibitor

Recommended For
Multiple Myeloma and Mantle Cell Lymphoma patients

Dosage
2.5 mg

Dosage Guidelines
As directed by a physician

Suitable For
Adults

Quantity
1 vial

Storage Instructions
Keep dry & cool place

Therapeutic Class
Anticancer - Proteasome Inhibitor

Route of Administration
Intravenous or subcutaneous use

Marketed By
Intas Pharmaceuticals Ltd.

Appearance
White or off-white lyophilized powder

Reconstitution Instructions
To be reconstituted with sterile 0.9% sodium chloride

Prescription/Non prescription
Prescription only

Shelf Life
2 years from manufacturing date

Warning
To be administered under supervision of a qualified physician

Patient Population
Adults only

Borviz 2.5 mg Trade Information

Minimum Order Quantity
2 Vials

Supply Ability
1000 Vials Per Month

Delivery Time
7 Days

About Borviz 2.5 mg

Last Chance to acquire the acclaimed Borviz 2.5 mg, a preeminent anticancer solution exclusively available by prescription. Formulated with the prime proteasome inhibitor Bortezomib, this valorous antineoplastic agent is trusted for the effective management of Multiple Myeloma and Mantle Cell Lymphoma in adults. Presented as a white or off-white lyophilized powder for intravenous or subcutaneous administration, Borviz 2.5 mg is supplied in a single-use vial, ensuring maximum efficacy. Clearance stock-crafted for excellence and convenience, and distributed by Intas Pharmaceuticals Ltd. Preserve in a cool, dry environment for optimal longevity.

Surface, Features & Use of Borviz 2.5 mg

Borviz 2.5 mg must be administered intravenously or subcutaneously by a qualified physician, ensuring direct and targeted application for optimal therapeutic impact. This vial features a white or off-white lyophilized powder designed for precise reconstitution with sterile 0.9% sodium chloride. Specifically developed for adult patients, its general use is the treatment of Multiple Myeloma and Mantle Cell Lymphoma, making it a vital choice in oncological therapy. Not suitable for use in children or without professional supervision.

Certifications, Goods Transport & Delivery of Borviz 2.5 mg

Borviz 2.5 mg is manufactured adhering to preeminent pharmaceutical standards in India, carrying necessary certifications for medical distribution. Efficient goods transport and reliable delivery systems ensure prompt receipt within the committed timeframe. Interested buyers can request product exchange or samples, subject to regulations and availability. The packaging preserves product efficacy and integrity, assuring safe transit from supplier or distributor to end-user, upholding every patient's right to uncompromised quality.

FAQ's of Borviz 2.5 mg:

Q: How is Borviz 2.5 mg administered to patients?

A: Borviz 2.5 mg must be given either intravenously or subcutaneously and is to be reconstituted with sterile 0.9% sodium chloride by a healthcare professional.

Q: What is the primary therapeutic use of Borviz 2.5 mg?

A: Borviz 2.5 mg is primarily indicated for the treatment of Multiple Myeloma and Mantle Cell Lymphoma in adult patients.

Q: When should Borviz 2.5 mg be used during the treatment process?

A: Borviz 2.5 mg should be used as directed by an oncologist or qualified physician as part of an established anticancer treatment protocol.

Q: Where should Borviz 2.5 mg be stored before use?

A: Keep Borviz 2.5 mg in a cool, dry place, away from direct sunlight and humidity, to maintain its efficacy until the expiration date.

Q: What is the process for reconstituting Borviz 2.5 mg before administration?

A: The powder in the vial should be carefully reconstituted with sterile 0.9% sodium chloride according to the physician's instructions prior to injection.

Q: Who can benefit most from Borviz 2.5 mg treatment?

A: Adult patients diagnosed with Multiple Myeloma or Mantle Cell Lymphoma under the supervision of a physician are the intended beneficiaries of Borviz 2.5 mg.

Tell us about your requirement